|

REGN7075 Clinical Trials

2 actively recruiting trials across 2 locations

▼ -1 trial since August 2026

Also known as: EGFRxCD28 bispecific immunotherapy, marlotamig

Pipeline

Phase 2: 2

Top Sponsors

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins1
  • Regeneron Pharmaceuticals1

Indications

  • Cancer2
  • Advanced/Metastatic Non-Small Cell Lung Cancer1
  • Advanced Non-Small Cell Lung Cancer1
  • Metastatic Non-Small Cell Lung Cancer1
  • Carcinoma, Non-Small-Cell Lung1

Birmingham, Alabama1 trial

A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

University of Alabama at Birmingham

Phase 2

Baltimore, Maryland1 trial

Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.